Immunocore Holdings plc (NASDAQ:IMCR) Receives $65.64 Consensus PT from Brokerages

Immunocore Holdings plc (NASDAQ:IMCR) has earned an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $65.64.

Several analysts have recently weighed in on IMCR shares. Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $72.00 to $38.00 in a report on Monday, November 11th. Needham & Company LLC reduced their target price on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Thursday, October 24th. Morgan Stanley reissued an “equal weight” rating and issued a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a research note on Friday, December 13th. Finally, UBS Group assumed coverage on Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 target price for the company.

Immunocore Price Performance

IMCR stock opened at $30.82 on Friday. Immunocore has a 1 year low of $27.69 and a 1 year high of $76.98. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -32.44 and a beta of 0.76. The company has a 50 day simple moving average of $31.23 and a 200 day simple moving average of $33.85.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. The company had revenue of $80.25 million during the quarter, compared to analysts’ expectations of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore’s revenue was up 23.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.59) EPS. Research analysts anticipate that Immunocore will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunocore

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP increased its position in Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock valued at $219,430,000 after buying an additional 668,382 shares in the last quarter. FMR LLC grew its stake in Immunocore by 0.5% in the third quarter. FMR LLC now owns 4,836,040 shares of the company’s stock valued at $150,546,000 after acquiring an additional 23,436 shares during the period. Primecap Management Co. CA increased its holdings in shares of Immunocore by 26.7% during the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after acquiring an additional 520,950 shares in the last quarter. Bellevue Group AG lifted its holdings in shares of Immunocore by 4.4% in the 3rd quarter. Bellevue Group AG now owns 1,205,464 shares of the company’s stock worth $37,526,000 after purchasing an additional 50,810 shares in the last quarter. Finally, Armistice Capital LLC grew its position in Immunocore by 495.1% in the 2nd quarter. Armistice Capital LLC now owns 976,000 shares of the company’s stock valued at $33,077,000 after purchasing an additional 812,000 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.